
Balaxi Pharmaceuticals Ltd. Hits Upper Circuit for the 2nd Straight Session on NSE, 19 November 2026
Updated: 19 Nov 2026 • 11:32 am
Posted by:

On 19 November 2026, Balaxi Pharmaceuticals Ltd. (BALAXI) hit the upper circuit on NSE at Rs 37.98, a 20% positive move from the previous close of Rs 31.65. The company's market cap stood at Rs 174.73 crore. The upper circuit price for the session was Rs 37.98.
The Balaxi Pharmaceuticals upper circuit streak has now run for 2 straight sessions. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.
Key Takeaways
- Balaxi Pharmaceuticals Ltd. (BALAXI) hit the upper circuit on NSE at Rs 37.98 on 19 November 2026.
- The session move was +20% against a previous close of Rs 31.65.
- Market capitalisation stood at Rs 174.73 crore with a PE ratio of 51.93.
- This is the 2nd straight session at the upper circuit, with the run starting on 18 November 2026.
- A price band is an exchange trading rule, not a view on the company or a recommendation.
Key Market Data
| Metric | Value |
|---|---|
| Stock | Balaxi Pharmaceuticals Ltd. |
| Current Price / LTP | Rs 37.98 |
| Day Move | 20% |
| Previous Close | Rs 31.65 |
| Day Open | Rs 31.8 |
| Day High | Rs 37.98 |
| Day Low | Rs 31.8 |
| Upper Circuit Price | Rs 37.98 |
| Upper Circuit Limit | Rs 37.98 |
| Market Cap | Rs 174.73 crore |
| Selected Exchange | NSE |
| PE Ratio | 51.93 |
All figures above are as of 19 November 2026, sourced from Univest market data for the NSE listing. Only fields present in the source for this session are shown.
Price Action and Trading Activity
Balaxi Pharmaceuticals Ltd. opened at Rs 31.8 on NSE, compared with a previous close of Rs 31.65. During the session, the stock traded between Rs 31.8 and Rs 37.98 before touching the upper circuit price of Rs 37.98.
The absolute day change was Rs 6.33, while the percentage move was 20%. The event figures are kept to a single exchange so the numbers stay comparable.
The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses NSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 37.98, which is the level the price reached.
The Balaxi Pharmaceuticals Upper Circuit Streak So Far
This is session 2 of an unbroken run for Balaxi Pharmaceuticals Ltd. The streak began on 18 November 2026, from a base price of Rs 26.47. Across the run the stock has moved 43.48% in total.
A repeated upper circuit matters more than a single one. It says the order book has stayed one-sided across multiple sessions rather than reacting to a single day of news, and for anyone holding the stock it means the price on screen has been hard to trade at for several days running.
This page is the running record for the streak and is updated each session rather than being replaced by a fresh article. That keeps one address for the event instead of splitting the same story across competing pages.
Why Balaxi Pharmaceuticals Ltd. Hit Upper Circuit
Balaxi Pharmaceuticals Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.
Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.
Within the session the stock reached the upper circuit level of Rs 37.98.
What the Balaxi Pharmaceuticals Upper Circuit Means
An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Balaxi Pharmaceuticals Ltd., the captured upper circuit price was Rs 37.98 on 19 November 2026.
The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.
Balaxi Pharmaceuticals Ltd. Fundamentals and Valuation
Available market data gives a fuller picture than price action alone. For Balaxi Pharmaceuticals Ltd., PE ratio was 51.93, PB ratio was 0.69, book value was Rs 46.04, EPS was 0.61, ROE was 0.59%, ROCE was 3.48%, dividend yield was 0% and debt-to-assets ratio was 0.22, on a market cap of Rs 174.73 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.
For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.
Peer and Sector Context
Balaxi Pharmaceuticals Ltd. belongs to the Trading industry. The peer table below uses available companies from the same sector or industry to give broader valuation context.
| Peer Company | Market Cap | PE | PB | ROE |
|---|---|---|---|---|
| Confidence Petroleum India Ltd. | Rs 2263.56 crore | 12.38 | 1.47 | 7% |
| Vintage Coffee & Beverages Ltd. | Rs 2205.38 crore | 28 | 3.98 | 17.91% |
| Aayush Art And Bullion Ltd. | Rs 2076.02 crore | 263.06 | 34.16 | 13.89% |
| Creative Newtech Ltd. | Rs 2072.83 crore | 27.13 | 5.17 | 21.38% |
| Khazanchi Jewellers Ltd. | Rs 1777.32 crore | 16.51 | 4.74 | 32.45% |
Several of these peers are far larger by market capitalisation than Balaxi Pharmaceuticals Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.
Balaxi Pharmaceuticals Ltd.'s PE ratio was 51.93, compared with an available peer PE average of 69.42, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.
Technical Snapshot
The technical snapshot adds context: RSI was 80.68.
What Readers Should Know
The main confirmed fact is that Balaxi Pharmaceuticals Ltd. hit the upper circuit on NSE at Rs 37.98 on 19 November 2026, with a 20% day move.
The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.
Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.
Frequently Asked Questions
Why did Balaxi Pharmaceuticals Ltd. hit upper circuit on 19 November 2026?
The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.
How many sessions has Balaxi Pharmaceuticals Ltd. hit upper circuit in a row?
This is session 2 of the current run, which began on 18 November 2026. This page is updated each session rather than replaced with a new article.
What was BALAXI share price on 19 November 2026?
The last traded price used in this article was Rs 37.98 on NSE. That price matched the upper circuit price captured for the event.
What was the upper circuit price for BALAXI?
The upper circuit price was Rs 37.98. The stated exchange upper circuit limit was Rs 37.98. The event numbers in this article are aligned to NSE.
What is Balaxi Pharmaceuticals Ltd.'s market cap and PE ratio?
Balaxi Pharmaceuticals Ltd.'s market cap was Rs 174.73 crore. PE ratio was 51.93.
Which exchange and data source were used?
The selected exchange was NSE. The article uses Univest market data available at the time of generation, captured on 19 November 2026.
Does hitting an upper circuit mean Balaxi Pharmaceuticals Ltd. is a buy or a sell?
No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.
Can you buy or sell Balaxi Pharmaceuticals Ltd. shares when the stock is at the upper circuit?
It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.
What happens the next trading session after an upper circuit?
There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.
What is the upper circuit limit set at for Indian stocks?
Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Balaxi Pharmaceuticals Ltd. the stated limit was Rs 37.98. For this session, Balaxi Pharmaceuticals Ltd. moved 20%.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Recent Articles

Crude Oil Price Today: Brent Steadies Near $92, WTI at $82 After Sharp Fall as Supply Surplus and US Stockpile Build Weigh
19 November 2026

Sensex Today Recovers 556 Points From Day's Low, Nifty Reclaims 25,300 as Auto Rally and FII Buying Offset Hawkish Fed Minutes
19 November 2026

Maruti Suzuki Share Price Jumps 6% as Nifty Auto Surges 3.6%; M&M, Hero MotoCorp, TVS Motor and Eicher Rally on Softer Crude
19 November 2026

LT Foods Share Price Jumps Up to 10% as Daawat Maker Buys US Brand Maya Kaimal for $5.8 Million
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Crude Oil Price Today: Brent Steadies Near $92, WTI at $82 After Sharp Fall as Supply Surplus and US Stockpile Build Weigh
Sensex Today Recovers 556 Points From Day's Low, Nifty Reclaims 25,300 as Auto Rally and FII Buying Offset Hawkish Fed Minutes
Maruti Suzuki Share Price Jumps 6% as Nifty Auto Surges 3.6%; M&M, Hero MotoCorp, TVS Motor and Eicher Rally on Softer Crude
LT Foods Share Price Jumps Up to 10% as Daawat Maker Buys US Brand Maya Kaimal for $5.8 Million
ICICI Life Insurance (ICICILIFE) Share Price Rises 2.04% Today

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





